Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Chronic Hepatitis B
Interventions
DRUG

PegIFN alfa-2a

180 μg/ 0.5 ml ,hypodermic injection once a week

Trial Locations (19)

Unknown

Wuhan Seventh People's Hospital, Wuhan

Changzhou Third People's Hospital, Changzhou

First Affiliated Hospital of Zhejiang University, Hangzhou

People's Hospital of Jiangsu Province, Nanjing

Nantong Third People's Hospital, Nantong

Suzhou Fifth People's Hospital, Suzhou

The First Affiliated Hospital of Soochow University, Suzhou

Taicang People's Hospital, Taicang

Wuxi Infectious Disease Hospital, Wuxi

Affiliated Hospital of Xuzhou Medical College, Xuzhou

Shandong Provincial Hospital, Jinan

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

Changhai Hospital Affiliated to Second Military Medical University, Shanghai

Huashan Hospital Affiliated to Fudan University, Shanghai

Ruijin Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai Public Health Clinical Center, Shanghai

Shanghai Third People's Hospital, Shanghai

Shuguang Hospital Affiliate to Shanghai University of Traditional Chinese Medicine, Shanghai

The Infectious Disease Hospital of Shanghai Huangpu Distric, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT02594293 - Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy | Biotech Hunter | Biotech Hunter